PeptideFactSheetsAn independent reference
Menu

Synthetic dipeptide-derived research compound · Fact sheet

Noopept

Also known as GVS-111 · Omberacetam

Noopept is a synthetic dipeptide-derived compound studied for cognitive disorders and in animal models. Rodent neurotrophin findings and limited regional clinical reports do not establish reliable memory enhancement in healthy people.

Not FDA approvedLimited or unclear evidence
Brain, mood & sleep

What is Noopept?

Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. It is a modified small molecule derived from peptide chemistry.

A finding of increased BDNF expression in rat hippocampus is a mechanistic result, not proof of human brain regeneration.

Benefits & claims

Readers encounter Noopept in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.

What the evidence supports

  • A rat study found changes in NGF and BDNF messenger RNA.
  • Cell work examined oxidative injury and tau-related effects rather than human Alzheimer disease progression.
  • The human comparative report does not establish prevention of dementia or enhancement in healthy adults.
Research areas
  • Cognition and memory
  • Neurologic or psychiatric research

Dosage & frequency

No established human regimen

The reviewed sources do not establish a human treatment amount or frequency for Noopept. Animal and laboratory exposures are not human regimens.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A finding of increased BDNF expression in rat hippocampus is a mechanistic result, not proof of human brain regeneration.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. FDA warning letter: unapproved nootropic claims

Side effects & risks

  • Long-term human safety and interactions are not established by the cited preclinical work.
  • Different routes and nonstandard preparations cannot inherit the tolerability of an oral regional medicine.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

The clinical comparative paper has limited accessible detail, while the primary mechanistic evidence comes from cells and rodents. General cognitive claims exceed that evidence.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 2 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

Sharper attention and more productivity on the first day

An author described clearer awareness, more self-control and greater productivity after a Noopept pill on the day of the post. A reply said sleep had remained good so far.

Reported use in this account

Product
Noopept pill
Amount
20 mg
Frequency
One exposure on the day described
Route
Not specified clearly
Duration
First-day experience

This was an early subjective response without formal attention testing. The author suspected ADHD but did not describe a confirmed diagnosis; a proposed later alpha-GPC combination was not an observed exposure.

Read the original account
Negative account · personal report

Marked fatigue, tinnitus and feeling detached

Another author described severe lethargy, tinnitus, poorer working memory and feelings of detachment after a first sublingual Noopept exposure. Some symptoms continued for the next few days.

Reported use in this account

Product
Noopept
Amount
30 mg
Frequency
One first exposure described
Route
Sublingual
Duration
Single exposure; symptoms were described over subsequent days

Other exposures described: Choline source; exact product not specified

A choline source was taken at the same time, and the product identity was not independently established. The account does not identify which substance caused the symptoms or establish a neurologic diagnosis.

Read the original account

Approval status

Noopept is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations

Summary

The human comparative report does not establish prevention of dementia or enhancement in healthy adults.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  2. pubmedNoopept stimulates the expression of NGF and BDNF in rat hippocampus.

    Rat hippocampal neurotrophin-expression experiment.

  4. fdaFDA warning letter: unapproved nootropic claims

    FDA identifies unapproved drug claims for named nootropics; this is an enforcement letter, not efficacy evidence.

How we assess sources · Suggest a correction